Annovis Bio, Inc.
$2.60
+0.78%Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.5).
Valuation inputs: P/E -2.5, earnings yield N/A, momentum +0.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -0.2%, ROIC -0.2%).
Profitability stack: net margin 0.0%, ROE -0.2%, ROIC -0.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +20.1%, momentum +0.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Annovis Bio, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Annovis Bio, Inc. Fair Value Envelope
No Revenue Data
ANVS has not reported any revenue values in the available annual periods.
Annovis Bio, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
ANVS has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
ANVS has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
ANVS has not reported any net profit margin values in the available annual periods.
Annovis Bio, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Annovis Bio, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Annovis Bio, Inc. Street Expectations Map
Wall Street analysts project that ANVS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 25.67, with estimates ranging from a low of 21.00 to a high of 30.00.
The consensus 1-year price target stands at 25.67, with estimates ranging from a low of 21.00 to a high of 30.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Annovis Bio, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.41M worth of ANVS shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
15.0K
63.60K
0
0.00
+64K
+$64K
6-9 Months
1.1M
2.35M
0
0.00
+2.3M
+$2.35M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Hoffman Michael B
Director
$2.21M
Maccecchini Maria-Luisa
Director, Officer: President & Ceo
$200K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $2.41M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
ANVS has not reported any dividend yield values in the available annual periods.
anvs Dividend History
Learning Layer
Related Guides
Build conviction on ANVS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.